Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234567 · ClinicalTrials.gov registry record
A Prospective Sub-Study of the Global Hypophosphatasia Registry
A clinical trial of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 30
- Enrollment target
- 12
- Study locations
NCT05234567 is a study of Hypophosphatasia that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT05234567, a study of Hypophosphatasia, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Conditions Studied
Interventions
- BIOLOGICAL Asfotase Alfa
Study Locations (12)
Ohio
- Clinical Trial Site - Cincinnati
- Clinical Trial Site - Columbus
Connecticut
- Clinical Trial Site - Hartford
Illinois
- Clinical Trial Site - Chicago
Massachusetts
- Clinical Trial Site - Boston
Missouri
- Clinical Trial Site - Kansas City
New York
- Clinical Trial Site - Mineola
Pennsylvania
- Clinical Trial Site - Pittsburgh
Tennessee
- Clinical Trial Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2028-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05234567
The ClinicalTrials.gov registry entry for NCT05234567 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 1 intervention - of which Asfotase Alfa is the first listed.
NCT05234567 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT05234567 about?
NCT05234567 is a clinical study titled "A Prospective Sub-Study of the Global Hypophosphatasia Registry". In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
What is the current status of trial NCT05234567?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-08-25. Estimated completion is 2028-07-18.
What conditions does trial NCT05234567 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT05234567?
The interventions under investigation include: Asfotase Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT05234567?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234567 being conducted?
This trial has 12 study locations across Connecticut, Illinois, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.